February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
February 2026 in “Figshare” A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
1 citations
,
October 2025 in “Journal of Allergy and Clinical Immunology” A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.
5 citations
,
March 2023 in “International Journal of Trichology” Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
March 2025 in “Clinical Cosmetic and Investigational Dermatology” The Tru9I variant in the VDR gene may influence alopecia areata risk and vitamin D levels.
July 2024 in “Journal of Investigative Dermatology” OR101 may effectively treat atopic dermatitis and similar skin conditions.
16 citations
,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
17 citations
,
July 2024 in “Frontiers in Oncology” New therapies and trials are needed for Merkel cell carcinoma, a tough skin cancer.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
7 citations
,
February 2025 in “Mammalian Genome” 16 citations
,
March 2022 in “Journal of Clinical Medicine” Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.
16 citations
,
March 2017 in “Oncotarget” SOCS3 treatment can prevent hair loss by stopping harmful immune responses.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.
3 citations
,
July 2024 in “Journal of Clinical Medicine” Alopecia areata patients have a higher risk of subclinical atherosclerosis, and carotid ultrasound can help assess their cardiovascular risk.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
2 citations
,
August 2023 in “Molecules” SH-340 may improve skin barrier and help treat atopic dermatitis.
1 citations
,
January 2025 in “Medicine” Targeting SOX proteins may improve cancer treatment by restoring immune function.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.